Head Cancer
16
5
5
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 16 trials
100.0%
+13.5% vs benchmark
6%
1 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (16)
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
Exercise and Nutritional Prehabilitation for Head and Neck Cancer Patients
Neurosensorial Disorder and Pain in Oral Cavity and Oropharynx Cancer Traited Patients (OCAPA)
PET MRI as a Staging Tool for Head and Neck Cancer
Evaluation of Quality of Life and Self-assurance and Social Support Earned for Non-cellular Head Cancer
Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer
Association Between Tinnitus and Hearing Loss in Locally Advanced Head and Neck Cancer Treated by Radiotherapy Alone or With Chemotherapy: a Prospective and Multicenter Study
Pivotal Study of Proton Radiotherapy Treatments Using Fixed Beam Chair-Based Delivery System
DNA Repair Enzyme Signature in Head and Neck Cancer (CHEMRAD)
Laser Therapy for the Prevention of Radiodermatitis in Head and Neck Patients
Education, Immigration and HPV Vaccination: an Informational Randomized Trial
Study Comparing Lymphoseek® vs. Albumin Nanocolloid in Head and Neck, Melanoma and Breast Cancer
Transcutaneous Electrical Nerve Stimulation (TENS) and Head and Neck Cancer Pain (HNC) (TENS & HNC)
Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck
Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer